# US 2025/0049926 A1 · Pharmaceutical compositions comprising modified betacyclodextrins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049926 A1
- Document ID: US20250049926A1
- Status: Published application
- Kind: A1
- Application number: 18/717,589
- Filed: 2022-12-14
- Published: 2025-02-13
- Earliest claimed: 2021-12-15
- Assignees: Sillajen, Inc.
- Applicants: Sillajen, Inc.
- Inventors: Luc BURY; Markus HEUBES; Gerrit HAUCK
- Web page: https://patentgrep.com/patent/US20250049926A1

## CPC

- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 35/00: Antineoplastic agents
- C08L 5/16: Cyclodextrin; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The present invention relates to pharmaceutical compositions comprising a compound of formula (I) as defined in the claims or a pharmaceutically acceptable salt thereof and a modified beta-cyclodextrin, as well as methods of using the pharmaceutical compositions for the treatment of neoplastic diseases such as cancer.

## Claims

### Claim 1

A pharmaceutical composition comprising a compound of formula (I)
or a pharmaceutically acceptable salt thereof and a modified beta-cyclodextrin.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the modified beta-cyclodextrin is sulfobutyl ether beta-cyclodextrin (SBE-beta-CD).

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the SBE-beta-CD has a degree of substitution of about 6 to about 7.5.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, wherein the SBE-beta-CD has an average degree of substitution of about 6 to about 7.5.

### Claim 5 (depends on 2)

The pharmaceutical composition of claim 2, wherein the SBE-beta-CD has an average degree of substitution of about 6.5.

### Claim 6 (depends on 2)

The pharmaceutical composition of claim 2, wherein the concentration of SBE-beta-CD in the pharmaceutical composition is up to about 400 mg/mL.

### Claim 7 (depends on 2)

The pharmaceutical composition of claim 2, wherein the concentration of SBE-beta-CD in the pharmaceutical composition is about 10 mg/mL to about 100 mg/mL.

### Claim 8 (depends on 2)

The pharmaceutical composition of claim 2, wherein the concentration of SBE-beta-CD in the pharmaceutical composition is about 30 mg/mL to about 50 mg/mL.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the concentration of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is up to about 3.5 mg/mL based on the compound of formula (I) as free base.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the concentration of the compound of formula (I) or a pharmaceutically acceptable salt thereof is about 1.5 mg/mL to about 2.5 mg/ml based on the compound of formula (I) as free base.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the concentration of the compound of formula (I) or a pharmaceutically acceptable salt thereof is about 2 mg/mL based on the compound of formula (I) as free base.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pH of the pharmaceutical composition is about 3.5 to about 7.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pH of the pharmaceutical composition is about 4 to about 6.5.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pH of the pharmaceutical composition is 4.5 to 6.5.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a salt as osmolality agent.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the salt is sodium chloride.

### Claim 17 (depends on 15)

The pharmaceutical composition of claim 15, wherein the salt concentration in the pharmaceutical composition is up to about 10 mg/mL.

### Claim 18 (depends on 15)

The pharmaceutical composition of claim 15, wherein the salt concentration in the pharmaceutical composition is about 0.5 mg/ml to about 8 mg/mL.

### Claim 19 (depends on 15)

The pharmaceutical composition of claim 15, wherein the salt concentration in the pharmaceutical composition is about 3 mg/mL.

### Claim 20 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof at a concentration of about 1 mg/mL to about 3 mg/mL based on the compound of formula (I) as free base, and SBE-beta-CD having an average degree of substitution of about 6 to about 7.5 at a concentration of about 10 mg/mL to about 100 mg/mL, and wherein the pH of the pharmaceutical composition is about 4 to about 6.5.

### Claim 21 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition consists essentially of the compound of formula (I) as free base, SBE-beta-CD having an average degree of substitution of about 6 to about 7.5, one or more buffering agents, optionally a salt, and optionally water, and wherein the pH of the pharmaceutical composition is about 4 to about 6.5.

### Claim 22 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition consists essentially of the compound of formula (I) as free base, at a concentration of about 1 mg/mL to about 3 mg/mL, SBE-beta-CD having an average degree of substitution of about 6 to about 7.5 at a concentration of about 10 mg/mL to about 100 mg/mL, one or more buffering agents, optionally a salt, and optionally water, and wherein the pH of the pharmaceutical composition is about 4 to about 6.5.

### Claim 23 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition consists essentially of the compound of formula (I) as free base at a concentration of about 1.5 mg/mL to about 2.5 mg/mL, SBE-beta-CD having an average degree of substitution of about 6 to about 7.5 at a concentration of about 30 mg/mL to about 50 mg/mL, one or more buffering agents, optionally a salt, and optionally water, and wherein the pH of the pharmaceutical composition is about 4 to about 6.5.

### Claim 24 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is one wherein the components and the quantities of each component per mL of pharmaceutical composition are as follows:
Component
Quantity
compound of formula (I) as free base
about 2 mg
SBE-β-CD, average degree of
about 40 mg
substitution of about 6 to about 7.5
citrate buffer
about 30 mM
sodium chloride
about 3 mg/mL
sodium hydroxide
quantity sufficient to adjust
the pH to 4.5 to 6.5
hydrochloric acid
quantity sufficient to adjust
the pH to 4.5 to 6.5
water for injection
q.s. to 1 mL
Total Volume
1 mL

### Claim 25 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is the compound of formula (I) as free base.

### Claim 26 (depends on 1)

The pharmaceutical composition of claim 1, wherein term “about” means a variation of no more than 5% of the relevant figure.

### Claim 27 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is suitable for intravenous administration.

### Claim 28 (depends on 1)

A pharmaceutical composition as defined in claim 1, for use in treating a neoplastic disease in a patient.

### Claim 29

(canceled)

### Claim 30 (depends on 1)

A method of treating a neoplastic disease in a patient in need thereof comprising:
administering a pharmaceutical composition as defined in claim 1 in a therapeutically effective amount to said patient.

### Claim 31

(canceled)

### Claim 32 (depends on 30)

The method of claim 30, wherein the neoplastic disease is a cancer selected from breast cancer, gastric cancer, colorectal cancer, liver cancer, endometrial cancer, ovarian cancer, esophageal cancer, lung cancer, Kaposi's sarcoma, cervical cancer, pancreatic cancer, melanoma, prostate cancer, bladder cancer, and leukemia.
